Date Published: 5 July 2011

Xarelto approved by FDA to reduce risk of blood clots after hip, knee replacements

Health News from the United States of America (USA)

The U.S. Food and Drug Administration has now approved Xarelto to reduce risk of blood clots after hip, knee replacements. The following information is from today's FDA Press Release about Xarelto:

The U.S. Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.

Xarelto is a pill taken once daily. According to the FDA people undergoing a knee replacement should take the medication for 12 days and patients undergoing a hip replacement procedure should take Xarelto for 35 days.

The safety and effectiveness of Xarelto was evaluated in patients undergoing hip replacement surgery and patients undergoing knee replacement surgery. Clinical studies were designed to identify occurrence of venous thromboembolic events (VTE), DVT, PE or death in patients treated. Treatment with Xarelto was compared to treatment with enoxaparin, a drug that prevents DVTs or blood clotting.

" Xarelto represents a new oral treatment option to help prevent blood clotting in patients receiving a hip or knee replacement,"
said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. Xarelto was reviewed by the Division of Hematology Products within the Office of Oncology Drug Products.

More than 6,000 patients undergoing hip or knee replacement surgery received Xarelto in clinical studies. Among patients undergoing knee replacement surgery, 9.7% of those treated with Xarelto had VTE compared with 18.8% of patients who received enoxaparin. In a study involving hip replacement surgery, 1.1% of patients who received Xarelto had VTE compared with 3.9% of those who received enoxaparin. In another study of hip replacement patients, 2.0% of those treated with Xarelto had VTE compared with 8.4% of those who received enoxaparin.

The most common side effect observed in patients treated with Xarelto was bleeding.

Other FDA approved drugs to prevent blood clotting include Lovenox (enoxaparin), generic versions of enoxaparin, Arixtra (fondaparinux), Fragmin (dalteparin) for hip replacement surgery only, Coumadin (warfarin) and heparin.

Xarelto is marketed in the U.S. by Raritan, N.J.- based Janssen Pharmaceuticals, Inc., a member of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Source: The U.S. Food and Drug Administration -

Also in the News:

Care at Critical Access Hospitals in rural areas of USA - 5 Jul '11

Do protein-based sport drinks benefit athletes' performance ? - 4 Jul '11

Dignity for elderly hospital patients in the UK - 1 Jul '11

Arcapta Neohaler approved by FDA to treat chronic obstructive pulmonary disease - 1 Jul '11

Biocompatible artificial DNA linker - 1 Jul '11

Food Advertising on TV encourages childrens preference for unhealthy foods - 1 Jul '11

Early communication at home helps children at school - 30 Jun '11

How dense tissue surrounding tumours drives tumour growth and development - 13 Jun '11

Depictions of human-like winged-beings have been discovered throughout the ancient world.

Although care has been taken when compiling this page, the information contained might not be completely up to date. Accuracy cannot be guaranteed. This material is copyright. See terms of use.

IvyRose Holistic 2003-2021.